Effect of Coq10 in STEMI patient.

The effect of COQ10 on plasma level of Hs-troponin and in hospital composit events and echocardiographic evidence of STEMI patients who admitted in Isfahan's Chamran hospital.

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200511047392N1

Enrollment

Registered

2020-06-29

Start date

2020-06-11

Completion date

Unknown

Last updated

2020-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

STEMI. Ischemic cardiomyopathy

Interventions

Intervention 1: Intervention group: STEMI in 18 - 85 years old treated with standard treatment and COQ 10 200 mg BID, Hs-troponin was measured before and 24 hour's after treatment, patients has been m

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: All STEMI patient that admitted in Chamran hospital that dont give Coq10 at last Dont have any arrhythmias (av block -VT) Dont be in cardiogenic shock Be at least 18 and up to 85 years old Typical chest pain that continued at least 20 mints

Exclusion criteria

Exclusion criteria: Every STEMI patients that dont be in 18-85 years old and give Coq10 or any type of anti inflammatory medication Cardiogenic shock-VSR Arrhythmias ( VT -AV block - VF)

Design outcomes

Primary

Measure	Time frame
Hs-troponin, Arrhythmias, Echocardiographic evidence. Timepoint: before intervention and 24 hour after and arrhythmias on admition time. Method of measurement: Hs-troponin kit , hospital monitoring and daily ECG.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactKian heshmat

Esfahan University of Medical Sciences

Meisamjmseu@gmail.com+98 31 3780 1438

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026